Over the past decade, the development of emicizumab, the first-in-class factor VIII (FVIII)-mimetic monoclonal antibody bispecific to activated factor IX and factor X, has ushered in a significant revolution in non-factor replacement therapy for patients with congenital FVIII deficiency or haemophilia A (HA). This groundbreaking therapy has been unequivocally...

In this issue of the Annals, Tan et al. on behalf of Singapore Myeloma Study Group presented the consensus guidelines on light chain (AL) amyloidosis.1 This is an encouraging effort as AL amyloidosis is a rare disease, with diagnostic and therapeutic challenges.  A comprehensive review examining its pathophysiology, diagnostic...

Recent reports have described an increased predominance of Gram-negative organisms (Escherichia coli, Klebsiella species ) among invasive bacterial infections in early- and late-onset neonatal sepsis in many settings.1-5 This changing pattern of infections is particularly concerning due to the global spread of drug resistance among Gram-negatives, leading to increasingly...

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease affecting about 25% of the general population.1,2 NAFLD has a broad disease spectrum ranging from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH)/liver cirrhosis, resulting in increased risk of developing not only liver-related complications but also extrahepatic morbidities.3...

Haemophilia A is an X-linked hereditary bleeding disorder caused by pathogenic genetic variants, which results in a deficiency of factor VIII (FVIII).1 The mainstay of treatment is FVIII replacement, which can be administered as prophylaxis or on-demand.2 While FVIII replacement has greatly improved outcomes in people with haemophilia A,...